CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D005234: Fatty Liver NIH

(Synonyms: Fatty Li, Fatty Liv, Fatty Live, Fatty Liver)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2815 TERN-101 Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D065626 Non-alcoholic Fatty Liver Disease NIH 1.00

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001397 Hepatic steatosis HPO 1.00

There is one clinical trial.

Clinical Trials


1 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.

NCT04328077 NASH - Nonalcoholic Steatohepatitis Drug: TERN-101 Other: Placebo
MeSH:Fatty Liver Non-alcoholic Fatty Liver Disease
HPO:Hepatic steatosis

Primary Outcomes

Measure: Subject incidence of adverse events for TERN-101 versus placebo

Time: 16 weeks

Secondary Outcomes

Measure: Percent change from baseline in ALT for TERN-101 versus placebo at 12 weeks

Time: 12 weeks

Description: Area under the curve

Measure: Plasma concentration of TERN-101 - AUC

Time: 12 weeks

Description: Maximum observed concentration

Measure: Plasma concentration of TERN-101 - Cmax

Time: 12 weeks

Description: Time to reach maximum measured plasma concentration

Measure: Plasma concentration of TERN-101 - Tmax

Time: 12 weeks

Description: Determination of half-life

Measure: Plasma concentration of TERN-101 - t1/2

Time: 12 weeks


HPO Nodes